TY - JOUR T1 - The probiotic effectiveness in experimental colitis is correlated with gut microbiome and host genetic features JF - bioRxiv DO - 10.1101/340331 SP - 340331 AU - Suwal, Sharmila AU - Wu, Qiong AU - Liu, Wenli AU - Liu, Qingya AU - Sun, Hongxiang AU - Liang, Ming AU - Gao, Jing AU - Zhang, Bo AU - Kou, Yanbo AU - Liu, Zhuanzhuan AU - Wei, Yanxia AU - Wang, Yugang AU - Zheng, Kuiyang Y1 - 2018/01/01 UR - http://biorxiv.org/content/early/2018/06/06/340331.abstract N2 - Current evidence to support extensive use of probiotics in inflammatory bowel disease is limited and factors contribute to the inconsistent effectiveness of clinical probiotic therapy are not completely known. Here, as a proof-of-concept, we utilized Bifidobacterium longum JDM 301, a widely used commercial probiotic strain in China, to study potential factors that may influence the beneficial effect of probiotics in experimental colitis. We found that the probiotic therapeutic effect was varied across individual mouse even with the same genetic background and consuming the same type of food. The different probiotic efficacy was highly correlated with different microbiome features in each mouse. Consumption of a diet rich in fat can change the host sensitivity to mucosal injury-induced colitis but did not change the host responsiveness to probiotic therapy. Finally, the host genetic factor TLR2 was required for a therapeutic effect of B. longum JDM 301. Together, our results suggest that personalized microbiome and genetic features may modify the probiotic therapeutic effect. ER -